QT Sense Secures €4M to Develop Quantum Sensing Platform
▼ Summary
– QT Sense, a biotech startup, has secured €4 million in funding to advance its Quantum Nuova platform, which enables real-time observation of biochemical activity in living cells.
– The platform uses fluorescent nanodiamond quantum sensors to detect dynamic cellular processes like oxidative stress and metabolic shifts, which are linked to disease development and treatment response.
– This technology provides a live view of individual cell behavior, offering insights beyond traditional static methods that rely on frozen or dead cells.
– The funding will support specific applications, including colorectal cancer research through the ONCO-Q program, to study drug effects and tumor vulnerabilities.
– The company, spun out of the University Medical Center Groningen, plans to evolve its prototype into a deployable discovery platform for laboratories and drug development programs.
A deep-tech biotech company has secured a significant investment to advance a platform that allows researchers to observe the inner workings of living cells in real time. QT Sense announced €4 million in new funding to accelerate the development of its Quantum Nuova technology. This innovative system provides a dynamic view of cellular processes, moving beyond the static snapshots offered by traditional laboratory methods that rely on frozen or non-living samples.
The investment round includes a €3 million seed investment led by Cottonwood Technology Fund. Existing investor QDNL Participations and an angel investor also contributed. Beyond this core funding, the startup received an additional €600,000 from the ONCO-Q programme for cancer research and €400,000 through the Quantum Forward Challenge to support collaborative work with research partners.
The Quantum Nuova platform’s capability hinges on ultra-sensitive fluorescent nanodiamond quantum sensors. These tiny sensors detect subtle biochemical signals within living cells, such as oxidative stress, metabolic shifts, and free radical activity. These processes are fundamental to understanding disease progression and cellular response to therapies, particularly in conditions like cancer, sepsis, and chronic inflammation. Until now, directly observing these dynamic events has been exceptionally difficult for scientists.
This technology enables researchers to watch how individual cells react to pharmaceutical compounds, adapt under pressure, or differentiate into subgroups. It delivers a layer of biological insight that genetics, conventional imaging, or fixed-cell analysis cannot achieve. The platform has already been utilized to study the effects of FDA-approved drugs on cellular activity. The dedicated ONCO-Q funding will direct this application toward colorectal cancer research, aiming to map stress and metabolic vulnerabilities in tumor models to aid future diagnostic and therapeutic development.
Spun out from the University Medical Center Groningen in 2024, QT Sense is built upon foundational academic work in quantum sensing and cellular biology. The company’s immediate objective is to evolve its current high-performance prototype into a robust, deployable discovery platform for laboratories and drug development programs. Planned enhancements focus on improving hardware reliability, increasing throughput, and expanding analytical capabilities. Early access units are slated for distribution to strategic partners to validate the technology through real-world applications.
The core innovation lies in using nanodiamond particles with specific quantum defects. When introduced near a living cell and stimulated by a laser, these nanodiamonds fluoresce. Their glow subtly shifts in response to minute chemical changes inside the cell, such as those occurring during drug exposure or stress. QT Sense’s system captures these precise changes and translates them into interpretable data for researchers.
This approach matters profoundly for biomedical research. Critical dynamic processes, like a cancer cell resisting treatment or an immune cell engaging a pathogen, unfold in real time and can be entirely missed by methods that only examine cells at a single, fixed endpoint. By offering a live, individual-cell perspective on behavior, the Quantum Nuova platform could reveal new insights into disease mechanisms and treatment efficacy, potentially guiding the creation of more effective therapies.
(Source: The Next Web)
